CNIO and Highlight Therapeutics test a compound against the most common skin cancer (IMAGE)

Centro Nacional de Investigaciones Oncológicas (CNIO)

CNIO and Highlight Therapeutics test a compound against the most common skin cancer

Caption

CNIO researcher Marisol Soengas (left) and Marisol Quintero, CEO of Highlight Therapeutics, at the entrance of the National Cancer Research Centre (CNIO).

Credit

Scienseed / CNIO

Usage Restrictions

Only to be used in the context of this feature story

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.